{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:11:59Z","timestamp":1793664719617,"version":"4.5.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","funder":[{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s12325-016-0315-8","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T16:07:44Z","timestamp":1458317264000},"page":"532-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure"],"prefix":"10.1007","volume":"33","author":[{"given":"John D.","family":"Sheppard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Comstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Cavet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"issue":"2","key":"315_CR1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1183\/09031936.06.00125404","volume":"27","author":"PJ Barnes","year":"2006","unstructured":"Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27(2):413\u201326.","journal-title":"Eur Respir J"},{"issue":"36","key":"315_CR2","doi-asserted-by":"crossref","first-page":"14616","DOI":"10.1073\/pnas.1309898110","volume":"110","author":"R Gupte","year":"2013","unstructured":"Gupte R, Muse GW, Chinenov Y, Adelman K, Rogatsky I. Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle. Proc Natl Acad Sci USA. 2013;110(36):14616\u201321.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"16","key":"315_CR3","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711\u201323.","journal-title":"N Engl J Med"},{"key":"315_CR4","unstructured":"Sendrowski DP JSD, Semes LP, Stern ME Anti-inflammatory Drugs. In: Bartlett JD, JS, editor. Clinical Ocular Pharmacology: Elsevier 2008;12:221\u201344."},{"issue":"5","key":"315_CR5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/ACI.0b013e32833dfa28","volume":"10","author":"BP Bielory","year":"2010","unstructured":"Bielory BP, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2010;10(5):469\u201377.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"315_CR6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11882-002-0061-7","volume":"2","author":"A Leonardi","year":"2002","unstructured":"Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep. 2002;2(4):325\u201331.","journal-title":"Curr Allergy Asthma Rep."},{"issue":"1","key":"315_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CN McGhee","year":"2002","unstructured":"McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33\u201355.","journal-title":"Drug Saf"},{"issue":"4","key":"315_CR8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2007.132621","volume":"92","author":"CE Pavesio","year":"2008","unstructured":"Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92(4):455\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"315_CR9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.eye.6701895","volume":"20","author":"JP Kersey","year":"2006","unstructured":"Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006;20(4):407\u201316.","journal-title":"Eye (Lond)."},{"issue":"2","key":"315_CR10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000328630","volume":"47","author":"MR Razeghinejad","year":"2012","unstructured":"Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66\u201380.","journal-title":"Ophthalmic Res"},{"issue":"1","key":"315_CR11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjmed.2010.08.011","volume":"124","author":"MR Razeghinejad","year":"2011","unstructured":"Razeghinejad MR, Myers JS, Katz LJ. Iatrogenic glaucoma secondary to medications. Am J Med. 2011;124(1):20\u20135.","journal-title":"Am J Med"},{"issue":"2","key":"315_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40123-013-0020-5","volume":"2","author":"U Pleyer","year":"2013","unstructured":"Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55\u201372.","journal-title":"Ophthalmol Ther."},{"issue":"6","key":"315_CR13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/0002-9394(75)90687-X","volume":"79","author":"HL Cantrill","year":"1975","unstructured":"Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79(6):1012\u20137.","journal-title":"Am J Ophthalmol"},{"key":"315_CR14","first-page":"187","volume":"4","author":"MF Armaly","year":"1965","unstructured":"Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol. 1965;4:187\u201397.","journal-title":"Invest Ophthalmol."},{"key":"315_CR15","first-page":"198","volume":"4","author":"B Becker","year":"1965","unstructured":"Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965;4:198\u2013205.","journal-title":"Invest Ophthalmol."},{"issue":"2","key":"315_CR16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00004397-199303320-00013","volume":"33","author":"RC Urban Jr","year":"1993","unstructured":"Urban RC Jr, Dreyer EB. Corticosteroid-induced glaucoma. Int Ophthalmol Clin. 1993;33(2):135\u20139.","journal-title":"Int Ophthalmol Clin"},{"issue":"4","key":"315_CR17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcrs.2010.10.051","volume":"37","author":"DF Chang","year":"2011","unstructured":"Chang DF, Tan JJ, Tripodis Y. Risk factors for steroid response among cataract patients. J Cataract Refract Surg. 2011;37(4):675\u201381.","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"315_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajo.2007.04.021","volume":"144","author":"D Shukla","year":"2007","unstructured":"Shukla D, Vidhya N, Prasad NM, Mahalakshmi R, Kolluru C, Krishnadas R. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol. 2007;144(3):453\u20134.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"315_CR19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/IAE.0b013e3181b32cfd","volume":"29","author":"GL Spaeth","year":"2009","unstructured":"Spaeth GL, Monteiro de Barros DS, Fudemberg SJ. Visual loss caused by corticosteroid-induced glaucoma: how to avoid it. Retina. 2009;29(8):1057\u201361.","journal-title":"Retina."},{"issue":"6","key":"315_CR20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00002512-199915060-00004","volume":"15","author":"RC Tripathi","year":"1999","unstructured":"Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15(6):439\u201350.","journal-title":"Drugs Aging"},{"key":"315_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000422359","volume":"21","author":"N Bodor","year":"1993","unstructured":"Bodor N. Design of novel soft corticosteroids. Curr Probl Dermatol. 1993;21:11\u20139.","journal-title":"Curr Probl Dermatol"},{"issue":"1","key":"315_CR22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/jop.1994.10.3","volume":"10","author":"N Bodor","year":"1994","unstructured":"Bodor N. Designing safer ophthalmic drugs by soft drug approaches. J Ocul Pharmacol. 1994;10(1):3\u201315.","journal-title":"J Ocul Pharmacol."},{"issue":"4","key":"315_CR23","doi-asserted-by":"crossref","first-page":"E820","DOI":"10.1208\/aapsj070479","volume":"7","author":"N Bodor","year":"2005","unstructured":"Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7(4):E820\u201333.","journal-title":"AAPS J."},{"issue":"2","key":"315_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0960-0760(91)90120-T","volume":"38","author":"P Druzgala","year":"1991","unstructured":"Druzgala P, Hochhaus G, Bodor N. Soft drugs\u201410. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991;38(2):149\u201354.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"315_CR25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/02713689109020329","volume":"10","author":"P Druzgala","year":"1991","unstructured":"Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991;10(10):933\u20137.","journal-title":"Curr Eye Res"},{"key":"315_CR26","doi-asserted-by":"crossref","unstructured":"A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology. 1998;105(9):1780\u20136.","DOI":"10.1016\/S0161-6420(98)99054-6"},{"key":"315_CR27","doi-asserted-by":"crossref","unstructured":"Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol. 1999;127(5):537\u201344.","DOI":"10.1016\/S0002-9394(99)00034-3"},{"issue":"1","key":"315_CR28","first-page":"31","volume":"23","author":"P Asbell","year":"1997","unstructured":"Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J. 1997;23(1):31\u20136.","journal-title":"CLAO J"},{"issue":"2","key":"315_CR29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0091-6749(98)70094-6","volume":"102","author":"SJ Dell","year":"1998","unstructured":"Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 1998;102(2):251\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"315_CR30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","volume":"123","author":"SJ Dell","year":"1997","unstructured":"Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol. 1997;123(6):791\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"315_CR31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0002-9394(14)70171-0","volume":"123","author":"MH Friedlaender","year":"1997","unstructured":"Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997;123(4):455\u201364.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"315_CR32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0161-6420(99)90077-5","volume":"106","author":"DG Shulman","year":"1999","unstructured":"Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 1999;106(2):362\u20139.","journal-title":"Ophthalmology"},{"issue":"11","key":"315_CR33","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0886-3350(98)80170-3","volume":"24","author":"R Stewart","year":"1998","unstructured":"Stewart R, Horwitz B, Howes J, Novack GD, Hart K. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg. 1998;24(11):1480\u20139.","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"315_CR34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00061198-199808000-00009","volume":"7","author":"GD Novack","year":"1998","unstructured":"Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7(4):266\u20139.","journal-title":"J Glaucoma"},{"key":"315_CR35","doi-asserted-by":"crossref","first-page":"789623","DOI":"10.1155\/2012\/789623","volume":"2012","author":"TL Comstock","year":"2012","unstructured":"Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623.","journal-title":"Int J Inflam."},{"issue":"5","key":"315_CR36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10792-012-9589-2","volume":"32","author":"M Amon","year":"2012","unstructured":"Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5%: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012;32(5):507\u201317.","journal-title":"Int Ophthalmol"},{"key":"315_CR37","first-page":"299","volume":"7","author":"MJ Coffey","year":"2013","unstructured":"Coffey MJ, Decory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol. 2013;7:299\u2013312.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"315_CR38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jcrs.2012.10.039","volume":"39","author":"SS Lane","year":"2013","unstructured":"Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013;39(2):168\u201373.","journal-title":"J Cataract Refract Surg"},{"issue":"9","key":"315_CR39","first-page":"1499","volume":"6","author":"SG Bannale","year":"2012","unstructured":"Bannale SG, Pundarikaksha HP, Sowbhagya HN. A prospective, open-label study to compare the efficacy and the safety of topical loteprednol etabonate and topical flurbiprofen sodium in patients with post-operative inflammation after cataract extraction. J Clin Diagn Res. 2012;6(9):1499\u2013503.","journal-title":"J Clin Diagn Res."},{"issue":"1","key":"315_CR40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0886-3350(01)01185-3","volume":"28","author":"MP Holzer","year":"2002","unstructured":"Holzer MP, Solomon KD, Sandoval HP, Vroman DT. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J Cataract Refract Surg. 2002;28(1):93\u20139.","journal-title":"J Cataract Refract Surg"},{"key":"315_CR41","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/OPTH.S30282","volume":"6","author":"MD Mifflin","year":"2012","unstructured":"Mifflin MD, Leishman LL, Christiansen SM, Sikder S, Hsu M, Moshirfar M. Use of loteprednol for routine prophylaxis after photorefractive keratectomy. Clin Ophthalmol. 2012;6:653\u20139.","journal-title":"Clin Ophthalmol."},{"issue":"7","key":"315_CR42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/ICO.0b013e3181967318","volume":"28","author":"M Erdurmus","year":"2009","unstructured":"Erdurmus M, Cohen EJ, Yildiz EH, et al. Steroid-induced intraocular pressure elevation or glaucoma after penetrating keratoplasty in patients with keratoconus or Fuchs dystrophy. Cornea. 2009;28(7):759\u201364.","journal-title":"Cornea"},{"issue":"10","key":"315_CR43","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/ICO.0b013e3181a3c52f","volume":"28","author":"EJ Holland","year":"2009","unstructured":"Holland EJ, Djalilian AR, Sanderson JP. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea. 2009;28(10):1139\u201343.","journal-title":"Cornea"},{"issue":"2","key":"315_CR44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.1993.9.157","volume":"9","author":"JD Bartlett","year":"1993","unstructured":"Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9(2):157\u201365.","journal-title":"J Ocul Pharmacol."},{"key":"315_CR45","doi-asserted-by":"crossref","unstructured":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75\u201392.","DOI":"10.1016\/S1542-0124(12)70081-2"},{"issue":"2","key":"315_CR46","first-page":"240","volume":"9","author":"M Hessen","year":"2014","unstructured":"Hessen M, Akpek EK. Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res. 2014;9(2):240\u201350.","journal-title":"J Ophthalmic Vis Res."},{"issue":"4","key":"315_CR47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICL.0000000000000042","volume":"40","author":"Y Wei","year":"2014","unstructured":"Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014;40(4):248\u201356.","journal-title":"Eye Contact Lens."},{"issue":"3","key":"315_CR48","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","volume":"138","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444\u201357.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"315_CR49","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/OPX.0000000000000600","volume":"92","author":"E Villani","year":"2015","unstructured":"Villani E, Garoli E, Termine V, Pichi F, Ratiglia R, Nucci P. Corneal confocal microscopy in dry eye treated with corticosteroids. Optom Vis Sci. 2015;92(9):e290\u20135.","journal-title":"Optom Vis Sci"},{"issue":"7","key":"315_CR50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/ICO.0000000000000436","volume":"34","author":"GE Boynton","year":"2015","unstructured":"Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI. Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation. Cornea. 2015;34(7):725\u201332.","journal-title":"Cornea"},{"issue":"1","key":"315_CR51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/jop.2010.0085","volume":"27","author":"JD Sheppard","year":"2011","unstructured":"Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther. 2011;27(1):23\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"315_CR52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/ICL.0000000000000049","volume":"40","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40(5):289\u201396.","journal-title":"Eye Contact Lens."},{"issue":"1","key":"315_CR53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4068\/cmj.2015.51.1.26","volume":"51","author":"HH Jung","year":"2015","unstructured":"Jung HH, Ji YS, Sung MS, Kim KK, Yoon KC. Long-Term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjogren\u2019s syndrome. Chonnam Med J. 2015;51(1):26\u201332.","journal-title":"Chonnam Med J."},{"issue":"6","key":"315_CR54","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ajo.2014.08.015","volume":"158","author":"H Lee","year":"2014","unstructured":"Lee H, Chung B, Kim KS, Seo KY, Choi BJ, Kim TI. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol. 2014;158(6):1172\u201383 e1.","journal-title":"Am J Ophthalmol."},{"issue":"6","key":"315_CR55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.clinthera.2012.04.024","volume":"34","author":"L Gong","year":"2012","unstructured":"Gong L, Sun X, Qu J, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther. 2012;34(6):1259\u201372 e1.","journal-title":"Clin Ther."},{"issue":"1","key":"315_CR56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.ICL.0000092071.82938.46","volume":"30","author":"H Ilyas","year":"2004","unstructured":"Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 2004;30(1):10\u20133.","journal-title":"Eye Contact Lens."},{"issue":"4","key":"315_CR57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s10384-012-0152-5","volume":"56","author":"V Oner","year":"2012","unstructured":"Oner V, Turkcu FM, Tas M, Alakus MF, Iscan Y. Topical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol. 2012;56(4):312\u20138.","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"315_CR58","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0149-2918(02)80007-8","volume":"24","author":"GJ Berdy","year":"2002","unstructured":"Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther. 2002;24(6):918\u201329.","journal-title":"Clin Ther"},{"issue":"7","key":"315_CR59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.optm.2010.10.011","volume":"82","author":"E Lu","year":"2011","unstructured":"Lu E, Fujimoto LT, Vejabul PA, Jew RL. Steroid-induced ocular hypertension with loteprednol etabonate 0.2%\u2014a case report. Optometry. 2011;82(7):413\u201320.","journal-title":"Optometry."},{"issue":"1","key":"315_CR60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/ICO.0b013e31815873c7","volume":"27","author":"EJ Holland","year":"2008","unstructured":"Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol\/tobramycin versus dexamethasone\/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27(1):50\u20135.","journal-title":"Cornea"},{"issue":"3","key":"315_CR61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2014.0107","volume":"31","author":"O Thanathanee","year":"2015","unstructured":"Thanathanee O, Sriphon P, Anutarapongpan O, et al. A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy. J Ocul Pharmacol Ther. 2015;31(3):165\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"315_CR62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF02849993","volume":"24","author":"SS Rhee","year":"2007","unstructured":"Rhee SS, Mah FS. Comparison of tobramycin 0.3%\/dexamethasone 0.1% and tobramycin 0.3%\/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. Adv Ther. 2007;24(1):60\u20137.","journal-title":"Adv Ther."},{"issue":"1","key":"315_CR63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1185\/030079908X253898","volume":"24","author":"EM White","year":"2008","unstructured":"White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin. 2008;24(1):287\u201396.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"315_CR64","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1185\/03007995.2012.659723","volume":"28","author":"M Chen","year":"2012","unstructured":"Chen M, Gong L, Sun X, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin. 2012;28(3):385\u201394.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"315_CR65","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/bjo.64.6.430","volume":"64","author":"BZ Biedner","year":"1980","unstructured":"Biedner BZ, David R, Grudsky A, Sachs U. Intraocular pressure response to corticosteroids in children. Br J Ophthalmol. 1980;64(6):430\u20131.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"315_CR66","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0161-6420(97)30052-9","volume":"104","author":"AK Kwok","year":"1997","unstructured":"Kwok AK, Lam DS, Ng JS, Fan DS, Chew SJ, Tso MO. Ocular-hypertensive response to topical steroids in children. Ophthalmology. 1997;104(12):2112\u20136.","journal-title":"Ophthalmology"},{"issue":"4","key":"315_CR67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9394(14)76256-7","volume":"112","author":"M Ohji","year":"1991","unstructured":"Ohji M, Kinoshita S, Ohmi E, Kuwayama Y. Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol. 1991;112(4):450\u20134.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"315_CR68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11596320-000000000-00000","volume":"14","author":"TL Comstock","year":"2012","unstructured":"Comstock TL, Paterno MR, Bateman KM, Decory HH, Gearinger M. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatr Drugs. 2012;14(2):119\u201330.","journal-title":"Paediatr Drugs"},{"key":"315_CR69","first-page":"177","volume":"5","author":"TL Comstock","year":"2011","unstructured":"Comstock TL, Paterno MR, Singh A, Erb T, Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011;5:177\u201386.","journal-title":"Clin Ophthalmol"},{"issue":"13","key":"315_CR70","first-page":"6027","volume":"49","author":"HT Nguyen","year":"2008","unstructured":"Nguyen HT, Samudre SS, Lattanzio FA, Williams PB, Sheppard JD. Loteprednol etabonate (Lotemax 0.5%) reduces inflammatory response associated with pterygium progression. Invest Ophthalmol Vis Sci. 2008;49(13):6027.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"315_CR71","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OPTH.S55259","volume":"8","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Mansur A, Comstock TL, Hovanesian JA. An update on the surgical management of pterygium and the role of loteprednol etabonate ointment. Clin Ophthalmol. 2014;8:1105\u201318.","journal-title":"Clin Ophthalmol."},{"key":"315_CR72","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2147\/OPTH.S32643","volume":"6","author":"R Fong","year":"2012","unstructured":"Fong R, Leitritz M, Siou-Mermet R, Erb T. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol. 2012;6:1113\u201324.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"315_CR73","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcrs.2012.09.013","volume":"39","author":"RK Rajpal","year":"2013","unstructured":"Rajpal RK, Roel L, Siou-Mermet R, Erb T. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2013;39(2):158\u201367.","journal-title":"J Cataract Refract Surg"},{"key":"315_CR74","unstructured":"Abessi B, Schultze RL, Eden RA, Brooksby LM. Comparison of efficacy of difluprednate 0.05% and loteprednol gel 0.5% after cataract surgery. In: Paper presented at: American cataract and refractive surgery annual symposium and congress (ASCRS). 2015."},{"key":"315_CR75","first-page":"2089","volume":"9","author":"CL Salinger","year":"2015","unstructured":"Salinger CL, Gordon M, Jackson MA, Perl T, Donnenfeld E. A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Clin Ophthalmol. 2015;9:2089\u201397.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"315_CR76","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/ICO.0000000000000475","volume":"34","author":"MO Price","year":"2015","unstructured":"Price MO, Feng MT, Scanameo A, Price FW Jr. Loteprednol etabonate 0.5% gel vs. prednisolone acetate 1% solution after descemet membrane endothelial keratoplasty: prospective randomized trial. Cornea. 2015;34(8):853\u20138.","journal-title":"Cornea"},{"key":"315_CR77","unstructured":"Williams J, Evans D, Torkildesn G, Sheppard J. Safety and efficacy of Lotemax gel compared to Restasis in the treatment of inflammation associated with dry eye disease. In: Paper presented at Annual Meeting of American Academy of Optometry. 2014;Program Number 145034."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0315-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:37:39Z","timestamp":1498279059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0315-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,17]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0315-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,17]]}}}